Categories
Markets

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

ACST Stock – (NASDAQ: ACST) is actually giving an update on the use

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the usage of its “at the market” equity offering program.

As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to implement an “at-the market” equity offering system under which Acasti may well issue and promote from time to time the common shares of its having an aggregate offering price of up to $75 million through the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January 27, 2021, Acasti issued an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 million. The ATM Shares were offered at prevailing market costs averaging US$1.0747 per share. No securities were sold throughout the facilities of the TSXV or maybe, to the expertise of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and outstanding as of March five, 2021.

The extra capital raised has strengthened Acasti’s balance sheet and often will deliver the Company with supplemental flexibility in its ongoing review process to check out as well as evaluate strategic options.

About Acasti – ACST Stock

Acasti is a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescription medications using OM3 greasy acids delivered both as totally free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical proof of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for individuals with severe HTG.

Forward Looking Statements – ACST Stock

Statements in this press release which are not statements of current or historical fact constitute “forward looking information” within the meaning of Canadian securities laws and “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking statements involve known and unknown risks, uncertainties, as well as other unknown elements that may result in the actual outcomes of Acasti to be materially different from historical success and as a result of any later outcomes expressed or even implied by such forward-looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, people are actually urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other related expressions to be uncertain and forward-looking. People are cautioned not to place undue reliance on these forward looking statements, which speak just as of the date of this particular press release. Forward-looking claims in this press release include, but are not confined to, information or statements about Acasti’s strategy, succeeding operations as well as the review of its of strategic alternatives.

The forward-looking claims contained in this press release are expressly qualified in the entirety of theirs by this cautionary statement, the “Special Note Regarding Forward Looking Statements” section in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor section of Acasti’s website at www.acastipharma.com. Many forward looking claims in that press release are produced as of the particular date of this particular press release.

ACST Stock – Acasti doesn’t undertake to redesign some such forward-looking statements whether as a consequence of information that is brand new , future events or otherwise, except as needed by law. The forward-looking claims contained herein are also subject generally to risks and assumptions and uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q under the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually giving an update on the use

Leave a Reply

Your email address will not be published. Required fields are marked *